Subscribe
shutterstock_96721225_steve_heap
Steve Heap / Shutterstock.com
7 January 2021AmericasMuireann Bolger

Generics petition Supreme Court to save PTAB patent trials

Generic drug makers are trying to persuade the US Supreme Court to retain an administrative process for challenging patents, in the latest bid to discredit the controversial decision handed down in Arthrex v Smith & Nephew.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Generics urge US Supreme Court to implement Copaxone ruling
27 January 2015   Generic drug makers Sandoz, Mylan and Natco have asked the US Supreme Court to immediately put into effect its ruling on the validity of a patent covering Teva’s multi-billion dollar multiple sclerosis drug Copaxone.


Editor's picks

Life sciences leaders recognised at LSPN Awards USA 2025
Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025

Editor's picks

Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025
Americas
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
6 May 2025
Americas
Why US patent reform is ‘essential’ for US economic prosperity and security
29 April 2025
Europe
Meril v Edwards: Harmonisation of obviousness at the UPC and the EPO
24 April 2025
Americas
WIPR Diversity & Inclusion reveals Top 100 People in IP for 2025
24 April 2025
Big Pharma
AstraZeneca unit faces class-action suit over alleged Soliris monopoly
17 April 2025

More on this story

Americas
Generics urge US Supreme Court to implement Copaxone ruling
27 January 2015   Generic drug makers Sandoz, Mylan and Natco have asked the US Supreme Court to immediately put into effect its ruling on the validity of a patent covering Teva’s multi-billion dollar multiple sclerosis drug Copaxone.

More on this story

Americas
Generics urge US Supreme Court to implement Copaxone ruling
27 January 2015   Generic drug makers Sandoz, Mylan and Natco have asked the US Supreme Court to immediately put into effect its ruling on the validity of a patent covering Teva’s multi-billion dollar multiple sclerosis drug Copaxone.

More features

Life sciences leaders recognised at LSPN Awards USA 2025
UK-India trade deal is ‘a missed opportunity for UK pharma’, says industry body
LSPN: Counsel grapple with AI’s impact on training and critical thinking
'Nothing can stand in the way of our work': Ukraine resumes IP system
LSPN: Trump's policy storm causing chaos and confusion
Taylor Wessing expands in Europe with Paris team
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
ResMed voids sleep apnoea tech patent at PTAB